Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
- About the CF Foundation
- Public Policy
- Drug Pipeline
- CFTR Modulators
- Get Involved
- Genetic Therapies
- Our Research Approach
- Clinical Trials
- Health Care Reform
- North American CF Conference
- Care Centers
- Patient Assistance
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Patient Registry
- Infection Prevention and Control
- Lung Transplantation
- In the Spotlight
- Coronavirus (COVID-19)
- Diversity, Equity, and Inclusion
- Intro to CF
- Clinician Resources
- Great Strides
- In Memoriam
- Adult Care
- Care Team
- CF-Related Complications
- CF Related Health Conditions
- Fertility and Reproductive Health
- Researcher Resources
- (-) Our Advocacy Work
During the annual event, volunteers advocated for the PASTEUR Act and the HELP Copays Act, two bipartisan pieces of legislation that could have substantial, positive impact on the CF community.
More than 60 teens from across the country — 25 of whom live with cystic fibrosis — participated online and on Capitol Hill in the Foundation’s Teen Advocacy Day to advocate for the CF community.
More than 160 people with CF and their loved ones from across the country advocated for a more robust antibiotics pipeline during the CF Foundation's virtual March on the Hill.
Nearly 200 teens from across the country -- nearly half living with cystic fibrosis -- participated in the Foundation's Virtual Teen Advocacy Day to advocate for the CF community.
More than 200 advocates gathered on Capitol Hill during the Cystic Fibrosis Foundation's 14th Annual March on the Hill, championing antibiotic research and development and other policy needs on behalf of people with CF.
On Monday, April 1, the CF Foundation joined 16 other patient and consumer groups in filing an amicus brief supporting vital patient protections and coverage expansion included in the Affordable Care Act in the appeal of the Texas v. United States decision, which struck down the constitutionality of the health care law in 2018.
Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.
The Cystic Fibrosis Foundation responds to the Institute for Clinical and Economic Review's assessment of the comparative clinical effectiveness and value of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
The Institute for Clinical and Economic Review (ICER) developed an assessment of the comparative clinical effectiveness and value of cystic fibrosis therapies. The Foundation provided input to help inform this process.